[Risk factors for cancer in patients with myositis. Clinical, immunological characteristics and the role of the anti-p155/140 antibody]

[Dermatomyositis-specific antibodies]

BACKGROUND

Idiopathic inflammatory myopathies are chronic systemic autoimmune diseases characterized by symmetrical proximal muscle weakness. The clinicopathological subdivision nowadays appears to be obsolete which is why the immunoserological classification has been developed.

OBJECTIVES

Dermatomyositis represents one the most important subsets of idiopathic inflammatory myopathy and dermatomyositis-specific autoantibodies play a significant role in this subset. The aim of this article was to present these autoantibodies with the help of the literature.

METHODS

This article presents the most important information about dermatomyositis including not only the classical anti-Mi-2 autoantibody but also the recently detected anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5 autoantibodies. The focus is on the frequency of these autoantibodies, the associated symptoms in adult and juvenile dermatomyositis cases and some special aspects from the literature.

RESULTS

All of the studies confirmed that these autoantibodies are particularly detectable in dermatomyositis. The results from the literature have recently shown that the frequency of the autoantibodies detected in juvenile cases is higher than the frequency of traditional autoantibodies (e.g. anti-Jo-1, anti-Mi-2 and anti-SRP).

CONCLUSION

It is useful to detect these autoantibodies in order to be able to make a better assessment of the clinical symptoms and prognosis during the course of the disease.